Update on HER-2 as a target for cancer therapy: The ERBB2 promoter and its exploitation for cancer treatment
-
Correspondence: Helen C Hurst hurst@icrf.icnet.uk
Breast Cancer Res 2001, 3:395-398 doi:10.1186/bcr329
Accesses
- Last 30 days: 27 accesses
- Last 365 days: 446 accesses
- All time: 5676 accesses
Cited by
BioMed Central: 4 citations
|
Hypothesis
A reason why the ERBB2 gene is amplified and not mutated in breast cancer Daniel Birnbaum, Fabrice Sircoulomb, Jean Imbert Cancer Cell International 2009, 9:5 (18 February 2009) |
|
Research article
Javier A Menendez, Alejandro Vazquez-Martin, Rocio Garcia-Villalba, Alegria Carrasco-Pancorbo, Cristina Oliveras-Ferraros, Alberto Fernandez-Gutierrez, Antonio Segura-Carretero BMC Cancer 2008, 8:377 (18 December 2008) Polyphenols found in extra virgin olive oil affect human breast cancer cell survival in vitro by suppressing HER2 oncogene over-expression and may have potential as a basis for new anti-breast cancer drugs in the future.
|
|
Protein family review
The AP-2 family of transcription factors Dawid Eckert, Sandra Buhl, Susanne Weber, Richard Jäger, Hubert Schorle Genome Biology 2005, 6:246 (28 December 2005) AP-2 transcription factors are involved in cell-type-specific stimulation of proliferation and the suppression of terminal differentiation during embryonic development. Members of the family are found in mammals (with five different proteins in human and mice), frogs and fish, as well as protochordates, insects and nematodes. |
|
Research article
Marion Lanteri, Laurence Ollier, Valérie Giordanengo, Jean-Claude Lefebvre Breast Cancer Research 2005, 7:R487-R494 (3 May 2005) |